Erratum on the BEACON Study Editorial

Kamyar Kalantar-Zadeh^a John A. Tayek^b^aUniversity of California Irvine Medical Center, Orange, Calif., and ^bHarbor-UCLA Medical Center, Torrance, Calif., USA

We would like to qualify the following sentence in our recent editorial on the BEACON trial [1], 'The investigators chose to ignore these warnings and to proceed with the trial of long-term outcomes (NCT01351675).' After communicating with some of the BEACON investigators we feel that the above statement does not reflect the facts. We understand that some members of the Beacon Steering Committee had a more critical view towards the study design of the trial, while they considered the trial scientifically challenging and a good opportunity for additional experimental studies of paramount importance; some of these have recently been published [2]. We also acknowledge the important contributions of the BEACON investigators and feel that the recently published paper on the description of the study [3] and our related editorial [1] provide a forum for further discussions including additional studies and analyses. Hence, as a constructive approach and given the recently published experimental data [2], we feel that the above-mentioned sentence should be removed.

References

- 1 Tayek JA, Kalantar-Zadeh K: The extinguished BEACON of bardoxolone: not a Monday morning quarterback story. *Am J Nephrol* 2013;37:208–211.
- 2 Zoja C, Corna D, Nava V, Locatelli M, Abbate M, Gaspari F, Carrara F, Sangalli F, Remuzzi G, Benigni A: Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. *Am J Physiol Renal Physiol* 2013;304:F808–F819.
- 3 de Zeeuw D, Akizawa T, Agarwal R, Audhya P, Bakris GL, Chin M, Krauth M, Lambers Heerspink HJ, Meyer CJ, McMurray JJ, Parving HH, Pergola PE, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Warnock DG, Wittes J, Chertow GM: Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: the occurrence of renal events (BEACON). *Am J Nephrol* 2013;37:212–222.